VIPS News Alert Vipshop Holdings Limited (VIPS) 23.71 11/18/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 11:00 PM

Vipshop Holdings Limited (VIPS) 23.71 $VIPS

3 Hot China ETFs For Singles Day
Zacks Funds - Seeking Alpha - 16 mins ago
Originally published November 11, 2014 Chinese and single make a perfect combination for a shopping day out on November 11. This is country’s Singles Day, when e-commerce players make quick bucks with heavy discounts and promotions to lure...
VIPS: 23.71 (-0.28), CHIQ: 13.56 (-0.13), KWEB: 37.04 (-0.63), CQQQ: 37.01 (-0.56), BABA: 110.81 (-3.44)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 4:39PM CST

JACK: 71.50 (+1.21), LZB: 22.58 (-0.16), ANV: 2.04 (+0.37), DL: 14.97 (+0.44), ENPH: 11.09 (+0.49), VIPS: 23.71 (-0.28), NLNK: 32.66 (+1.75), WLT: 2.93 (-0.09), ODP: 6.69 (unch), JDST: 14.66 (-3.93)

Vipshop, Jack in the Box Rise In After-Hours Trading
at Investor's Business Daily - Tue Nov 18, 4:04PM CST
Stocks finished higher Tuesday, with the Dow Jones industrial average and the S&P 500 making fresh all-time highs and the Nasdaq overcoming Monday's weakness with a 14 1/2-year high. Volume was higher than Monday on the NYSE and slightly lower on the...
AGN: 213.37 (+4.17), JACK: 71.50 (+1.21), ACT: 269.60 (+21.66), VIPS: 23.71 (-0.28)

Vipshop guides in-line; both revenue and spending grow rapidly
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 3:22PM CST

VIPS: 23.71 (-0.28)

Vipshop (VIPS) Stock Is Higher in After-Hours Trading Today After Earnings Beat
at The Street - Tue Nov 18, 3:17PM CST
Vipshop (VIPS) is gaining after-hours Tuesday after beating analysts' estimates for earnings and revenue in the third quarter.
VIPS: 23.71 (-0.28)

Vipshop Holdings beats by $0.01, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Nov 18, 3:03PM CST

VIPS: 23.71 (-0.28)

Vipshop Reports Unaudited Third Quarter 2014 Financial Results
PR Newswire - Tue Nov 18, 3:01PM CST
Vipshop Holdings Limited (NYSE: VIPS), China's leading online discount retailer for brands ("Vipshop" or the "Company"

, today announced its unaudited financial results for the quarter ended September 30, 2014.
VIPS: 23.71 (-0.28)

Stocks Add To Gains; Ambarella Ramps Up
at Investor's Business Daily - Tue Nov 18, 1:58PM CST
Stocks marched to fresh session highs in late trading Tuesday. The Nasdaq rallied 0.8% to another multiyear high, while the S&P 500 rose 0.7%, another record high. Meanwhile, the Dow Jones industrial average gained 0.4%. NYSE volume was tracking...
AMBA: 49.67 (+0.89), GPRO: 84.10 (+2.60), VIPS: 23.71 (-0.28), TASR: 20.13 (+0.62)

Stocks Hold Near Fresh Milestones; Actavis Hits New High
at Investor's Business Daily - Tue Nov 18, 12:33PM CST
Stocks were near their best levels of the session Tuesday afternoon amid news from Japan and a jump in homebuilder confidence. The Nasdaq rose 0.7%. Earlier, it touched a fresh 14-1/2-year high. The S&P 500 climbed 0.5% to an all-time high....
AGN: 213.37 (+4.17), VIPS: 23.71 (-0.28), VRX: 141.94 (+5.21), ACT: 269.60 (+21.66), HD: 95.98 (-2.05), BITA: 93.99 (+4.61)

What to Expect When Vipshop Holdings (VIPS) Reports Third-Quarter Earnings
at The Street - Tue Nov 18, 9:12AM CST
Shares of Vipshop Holdings (VIPS) are down in early morning trading ahead their of 2014 third quarter earnings report after the market close today.
VIPS: 23.71 (-0.28)

Vipshop Leads 4 Top Stocks With Bolting RS Lines
at Investor's Business Daily - Tue Nov 18, 7:02AM CST
Going with the flow is all well and good, but rising head and shoulders above the crowd is a sign of a solid stock. Today's Screen of the Day features four companies that have bolting Relative Strength lines. An RS line tracks how a stock is doing...
ZTS: 44.19 (-0.04), ABT: 43.70 (-0.01), VIPS: 23.71 (-0.28), BIDU: 242.75 (-1.40), PFE: 30.59 (+0.27), JMEI: 23.21 (-0.43), COST: 139.21 (+0.74), IDXX: 149.97 (+0.56), LITB: 7.64 (-0.13), BABA: 110.81 (-3.44)

Notable earnings after Tuesday's close
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:35PM CST

LZB: 22.58 (-0.16), JACK: 71.50 (+1.21), VIPS: 23.71 (-0.28), GBDC: 17.43 (+0.14), PETM: 73.62 (+0.01)

Stocks Rally Off Lows, Finish Mixed For The Day
at Investor's Business Daily - Mon Nov 17, 4:11PM CST
Stocks recovered somewhat from morning losses to end mixed Monday. The Nasdaq finished down 0.4% while the S&P 500 and the Dow each added 0.1%. Volume in the stock market today was slightly heavier on the NYSE but lighter on the Nasdaq, according to...
VIPS: 23.71 (-0.28), HD: 95.98 (-2.05), BIDU: 242.75 (-1.40), RHT: 63.22 (+0.22), MIK: 21.86 (+0.21), TSN: 42.65 (-0.38), BITA: 93.99 (+4.61), ATHM: 41.13 (-1.72)

Stock Movers: Why 4 China Nets Were Big Losers Today
at Investor's Business Daily - Mon Nov 17, 3:50PM CST
Chinese Internet stocks have grown at a remarkable pace in recent years. But the sector has paused recently as China's overall economic growth slowed. Among the stocks showing the biggest downward movement on today's IBD Stocks On The Move list are...
VIPS: 23.71 (-0.28), PWRD: 19.09 (+0.02), JD: 25.41 (+0.41), CMGE: 26.16 (+1.97), WBAI: 24.60 (-0.52), BABA: 110.81 (-3.44)

JD.com -7.6% after mixed results, in-line guidance; Vipshop -3.8%
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 1:16PM CST

VIPS: 23.71 (-0.28), JD: 25.41 (+0.41)

Vipshop Benefited From Promotions in Q3: Analysts
at Investor's Business Daily - Mon Nov 17, 1:11PM CST
Vipshop Holdings (VIPS), the Guangzhou, China-based flash sales apparel seller, is expected to continue to ride a growth wave when it reports third-quarter earnings after the close Tuesday. The consensus estimate of 25 analysts polled by Thomson...
VIPS: 23.71 (-0.28)

Will Vipshop Holdings Limited (VIPS) Surprise Q3 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 9:20AM CST
Vipshop Holdings Limited (VIPS) is set to report the third-quarter 2014 results on Nov 18. Last quarter, the company posted a 20.0% positive earnings surprise. Let's see how things are shaping up for this announcement.
ESL: 116.15 (+0.02), VIPS: 23.71 (-0.28), KR: 58.52 (+0.23), BBY: 34.90 (-0.39)

Cramer's Mad Money - I'm Sorry I Ever Heard Of Globalstar (11/14/14)
SA Editor Miriam Metzinger - Seeking Alpha - Sun Nov 16, 5:05AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday November 14. I'm Sorry I Ever Heard of Globalstar (NYSEMKT: GSAT ) . Other stocks mentioned: Qualcomm (NASDAQ: QCOM ), Skyworks (NASDAQ: SWKS ) One of the...
GPRO: 84.10 (+2.60), VIPS: 23.71 (-0.28), HD: 95.98 (-2.05), SWKS: 63.90 (+1.75), GMCR: 157.10 (+2.60), HAL: 48.54 (-0.69), DECK: 92.20 (-0.52), TSN: 42.65 (-0.38), GSAT: 2.55 (-0.25), WWAV: 36.74 (+0.21), HAIN: 107.41 (-1.00), JACK: 71.50 (+1.21), MHR: 4.62 (+0.05), CBRL: 118.83 (+0.39), LRCX: 79.29 (+1.50), QCOM: 72.01 (+1.61), EOG: 97.67 (+1.32), FL: 54.83 (+0.03), MBLY: 47.33 (+0.35), APC: 89.39 (+0.42), BHI: 63.55 (-1.68), BABA: 110.81 (-3.44), PETM: 73.62 (+0.01), CRM: 62.47 (-0.04)

Jim Cramer's 'Mad Money' Recap: Bull Market Rides on G20 Weekend
at The Street - Fri Nov 14, 7:38PM CST
Cramer says next week's market moves will tip on path to peace in Ukraine. Meanwhile he'll be watching the food sector starting with Tyson's earnings.
VIPS: 23.71 (-0.28), NKE: 96.47 (+0.41), GMCR: 157.10 (+2.60), SKX: 58.43 (+1.39), WMT: 83.79 (+0.22), BBY: 34.90 (-0.39), HP: 77.90 (-0.35), GSAT: 2.55 (-0.25), JACK: 71.50 (+1.21), SWI: 50.51 (+0.52), FL: 54.83 (+0.03), GRPN: 7.37 (-0.20), MBLY: 47.33 (+0.35), BHI: 63.55 (-1.68), GPRO: 84.10 (+2.60), HD: 95.98 (-2.05), DECK: 92.20 (-0.52), TSN: 42.65 (-0.38), HCA: 67.23 (+1.50), UA: 69.37 (+0.48), AA: 17.16 (+0.33), TJX: 61.64 (+0.10), LRCX: 79.29 (+1.50), YELP: 57.46 (-0.54), PSEC: 9.68 (+0.02), ROST: 81.28 (-0.06)

Vipshop, China E-Commerce Firms To Report Earnings
at Investor's Business Daily - Fri Nov 14, 3:41PM CST
Three of China's big e-commerce companies will report third-quarter earnings next week. China's largest direct sale e-commerce company JD.com (JD), known as China's Amazon (AMZN), will report before the open Monday. Vipshop Holdings (VIPS), a Chinese...
AMZN: 324.93 (+1.88), VIPS: 23.71 (-0.28), JMEI: 23.21 (-0.43), JD: 25.41 (+0.41)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

BAIC FOTON Eyes African Market with Strategic Moves

Revving Up for Africa Alright, gearheads and number-crunchers, strap in. BAIC FOTON is making headlines again, and this time they’re zooming right into Africa—like they're claiming pole position on a circuit that's been ignored by many. They’re calling it a “Drive to Great!” but what does that mean for us investors who aren’t just in it for the entertainment?...

RYBREVANT's Promising Results in HNSCC Treatment

Impressive Outcomes for RYBREVANT FASPRO in Head and Neck Cancer Tucked away in the endless cycle of drug trials, a glimmer of hope shines through with new data on RYBREVANT FASPRO in treating head and neck squamous cell carcinoma (HNSCC). This science talk might not rattle the ticker tape directly on NYSE:JNJ, but it has all the makings of a game-changer in the oncology...

Sac-TMT's Phase III Success Shifts Lung Cancer Paradigm

A New Era in Lung Cancer Treatment? Sac-TMT, the novel antibody-drug conjugate (ADC), just might be shaking up the non-small cell lung cancer (NSCLC) treatment landscape, and boy, is it making waves. Just when you think you’ve seen it all, here comes sacituzumab tirumotecan (sac-TMT), offering a glimmer of hope for patients whose treatment options have dwindled after...

Dr. Boonipat Inspires Future Women Surgeons at Texas Tech

Sowing Surgical Seeds in Lubbock In Lubbock, Texas, something meaningful unfolded—an event the big market players would hardly blink at, but a significant step for the future of medicine. Led by Dr. Thanapoom "Mo" Boonipat, the founder of FacePlus Plastic Surgery Institute, a unique suturing workshop provided premed students at Texas Tech University hands-on experience...

Gildan Activewear Faces Legal Battle Over Alleged Fraud

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Hims & Hers Faces FTC Heat: Investor Class Action Looms

Trouble Is Brewing for Hims & Hers Investors This isn't your typical quiet stroll through the park when it comes to Hims & Hers Health, Inc. (NYSE: HIMS). We're talking about a full-blown legal showdown that's unfolding faster than you can say 'telehealth scandal.' October 25, 2026, saw the kind of announcement that makes seasoned investors' hearts skip a beat if they've...

Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Firefox Champions Privacy with Iconic Internet Campaign

Rekindling the Internet’s Golden Days with Firefox There’s something almost poetic about Firefox hustling to win back its old users by launching a campaign with legendary internet icons. The backdrop? A digital landscape where privacy feels about as common as a unicorn sighting. Mozilla's pulling a major nostalgia card, and I'm here for it—sort of like how vinyl...

Ivonescimab Promises New Hope for Advanced BTC Patients

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...